Abstract
Overview
This report presents the findings of a global survey on current treatments and
prescribing practices for Ischaemic Stroke, Haemorrhagic Stroke and Transient
Ischaemic Attack (TIA). These findings were made following the participation
of more than 230 clinics worldwide, which provided detailed information on
their treatment practices.
Global quantitative data on treatments and drug prescribing practices for
Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA),
provided by more than 230 clinics in 41 countries.
More than 98% of study participants are practicing physicians, working in
areas of Stroke treatment. Of these, 65% are specialists in Stroke treatment.
Leading participant countries were USA, Italy, India, Canada, Japan, Germany,
Spain, Belgium and China.
More than 60% of the clinical centres participating in this study were
hospital specialist Stroke units, specialist Stroke practices or private
Stroke clinics.
Detailed information on drugs classes used in the treatment of patients with
Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA),
together with population-based drug prescribing profiles.
Quantitative prescribing data on specific antiplatelet, anticoagulant,
thrombolytic and other drugs used in the treatment of Ischaemic Stroke,
Haemorrhagic Stroke and Transient Ischaemic Attack (TIA).
The percentage of Ischaemic Stroke patients prescribed the antiplatelets
aspirin (e.g. AsproR), dipyridamole (e.g. PersantineR), clopidogrel (e.g.
PlavixR), aspirin/dipyridamol (e.g. AsasantinR), ticlopidine (e.g. TiclidR)
and others (specified).
The percentage of Ischaemic Stroke patients prescribed the coagulants warfarin
(e.g. CoumadinR), heparin (e.g. HepaleanR), dicoumarol (e.g. Dicoumarol),
antithrombin III (e.g. Thrombate IIIR), argatroban (e.g. NovastanR),
bivalirudin (e.g. AngiomaxR), sandoparin (e.g. CertoparinR), enoxaparin (e.g.
LovenoxR), ethyl biscoumacetate (e.g. TromexanR), nadroparin (e.g.
FraxiparineR) or others (specified)
The percentage of Ischaemic Stroke patients prescribed the thrombolytic drug
Tissue Plasminogen Activator (e.g. AlteplaseR) or others (specified).
The percentage of Haemorrhagic Stroke patients prescribed clotting factor
(e.g. vitamin K), clotting proteins (e.g. prothrombin), calcium channel
blockers (e.g. nimodipine), antihypertensives, platelets, plasma or other
(specified).
Prescribing practices on the use of specific drug combinations, used in the
treatment of Ischaemic and Haemorrhagic Stroke.
The percentage of Haemorrhagic Stroke patients treated surgically by aneurysm
clipping, endovascular treatment of aneurysms, surgical arteriovenous
malformation (AVM) removal, steriotactic radiosurgery, endovascular treatment
of AVMs, removal of haematoma, ventriculostomy, carotid endarterectomy,
craniotomy and others (specified).
In-depth information provided by physicians on current limitations in the
diagnosis of stroke and current issues and challenges in the Stroke treatment.
Introduction
In 2008, the World Stroke Congress reported that 20 million Stroke events
occur globally each year and account for 5.7 million deaths. Stroke is now the
second most common cause of death worldwide and a major cause of disability.
The incidence of Stroke is expected to increase by 30% over the next decade
(6th World Stroke Congress, Vienna, Austria, 24th-27th September 2008).
In a field where therapies are often unsatisfactory, physicians seek to extend
their understanding and use of available treatments to improve patient
outcomes. Knowledge in these areas is also important to drug developers, who
seek a better understanding of prescribing practices and treatment needs and
limitations from the clinician' s perspective, as part of their own efforts to
develop more effective therapies. To meet interest in these areas, a global
survey on current treatments and drug prescribing practices for Stroke, has
been conducted. This survey involved the participation of more than 230
clinical centres in 41 countries. 2
| 
View Cart
